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Abstract
Cystic Fibrosis (CF) is an inherited pleiotropic disease that results from abnormalities in the gene that codes for the chloride
channel, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CF patients are frequently colonized by several
pathogens, but the mechanisms that allow colonization in spite of apparently functional immune systems are incompletely
understood. In this paper we show that blood peripheral monocytes isolated from CF patients are found in an endotoxin
tolerance state, yet this is not due to a deficient TLR activation. On the other hand, levels of the amplifier of inflammatory
responses,TREM-1(TriggeringReceptorExpressed onMyeloidcells),arenotablydown-regulatedinmonocytesfrompatients,in
comparisontothoseextractedfromhealthyvolunteers.Furthermore,thesolubleformofTREM-1(sTREM-1)wasnotdetectedin
the sera of patients. Additionally, and in strict contrast to patients who suffer from Chronic Obstructive Pulmonary Disease
(COPD), CF monocytes challenged ex vivo with LPS neither up-regulated membrane-anchored TREM-1 nor sTREM-1. Finally,
similar levels of PGE2 expression and p65 translocation into the nucleus were found in both patients and healthy volunteers,
thus suggesting that TREM-1 regulation is neither controlled by PGE2 levels nor by p65 activation in this case. However, PU.1
translocation into the nucleus was significantly higher in CF monocytes than in controls, suggesting a role for this transcription
factor in the control of TREM-1 expression. We conclude that down-regulation of TREM-1 expression in cystic fibrosis patients is
at least partly responsible for the endotoxin tolerance state in which their monocytes are locked.
Citation: del Fresno C, Go ´mez-Pin ˜a V, Lores V, Soares-Schanoski A, Ferna ´ndez-Ruiz I, et al. (2008) Monocytes from Cystic Fibrosis Patients Are Locked in an LPS
Tolerance State: Down-Regulation of TREM-1 as Putative Underlying Mechanism. PLoS ONE 3(7): e2667. doi:10.1371/journal.pone.0002667
Editor: Oliver Eickelberg, University of Giessen Lung Center, Germany
Received February 26, 2008; Accepted June 13, 2008; Published July 16, 2008
Copyright:  2008 del Fresno et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MEC and FMMA
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: elopezc.hulp@salud.madrid.org
. These authors contributed equally to this work.
Introduction
Cystic fibrosis (CF), also called mucoviscidosis, is a complex,
pleiotropic disease that affects all exocrine epithelia. CF results
from abnormalities in the gene that codes for the chloride channel
termed CF Transmembrane Conductance Regulator (CFTR),
which belongs to the extended family of ATP-binding cassette
(ABC) transporter ATPases [1,2]. This transmembrane glycopro-
tein is expressed in some epithelia, and controls chloride flux
across cell surfaces. In addition, it down-regulates transepithelial
sodium transport, regulates calcium-activated chloride channels
and potassium channels, and may also serve important functions
in exocytosis [1].
Some clinical features of CF include injuries of primary organs
(pancreas, sinus, liver, intestine and exocrine pancreas) and
secondary complications such as malnutrition, and diabetes.
However, morbidity and mortality of CF patients are usually the
result of chronic lower airway bacterial infections and inflamma-
tion of the lungs [3]. Repeated episodes of polymicrobial infection
in these patients cause a progressive deterioration of lung tissue, a
decline in pulmonary function and, ultimately, respiratory failure
and death in 90% of CF patients [4]. In spite of the critical role
played by pulmonary infections in these patients, the host factors
that permit bacterial endobronchial colonization of the CF airway
are poorly understood. It has been proposed that defective
transmembrane conductance facilitates bacterial adherence to the
respiratory epithelium, and that alterations in the sodium and
chloride concentrations in the periciliary fluid impair the activity
of defensins. Other authors claim that a deficit of hydrophilic
surfactant proteins contributes to the inefficiency of the cellular
inflammatory response to invading bacteria [5]. These observa-
tions, in turn, point to a deregulation of the innate immune
systems in CF patients, and provoke a thorough analysis of the
interplay between bacterial and host factors.
Recently, the immunoglobulin-related transmembrane receptor
termed triggering receptor expressed on myeloid cells, (TREM)-1,
has been recognized as an important element of the immune
response, which strongly enhances leukocyte activation in the
presence of microbial products [6,7]. TREM-1 is mainly expressed
on monocytes and neutrophils, and its levels at cell surface are up-
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[6,7,8,9]. Although the cellular signaling events downstream of
TREM-1 engagement are incompletely understood, recently
reported data suggest that receptor expression is essential for
mounting an adequate inflammatory and cytotoxic response to
polymicrobial sepsis [10]. This has been particularly demonstrated
by in vivo silencing of TREM-1 in a fecal peritonitis mouse model,
which resulted in a blunted inflammatory response and increased
mortality [7,10,11]. Also along these lines, receptor expression is
significantly higher in the course of infectious diseases. Current
evidence suggests that TREM-1 levels could represent a valuable
marker of infection in several pathological conditions including
sepsis [12,13,14]. LPS-induced receptor expression appears to be
at least partly mediated by endogenous prostaglandin E2 (PGE2);
this triggers EP4- and cAMP/protein kinase A-dependent
mechanisms that are followed by p38 MAPK activation and
PI3K-mediated signaling [13].
In addition to the membrane-bound form, a soluble TREM-1
variant (sTREM-1) has been detected in mouse and human serum
[15,16]. In particular, clinical studies have reported the presence
of sTREM-1 in patients’ serum and in bronchioalveolar lavage
fluid [17,18]. This soluble form has been found at particularly high
concentrations in fluids from patients with microbial infections
[7,15,19] and with ventilator-associated pneumonia [20]. Other
authors also report an up-regulation of sTREM-1 in plasma from
septic patients versus those suffering from systemic inflammatory
response syndrome (SIRS) [19]. Altogether, current evidence
strongly suggests an important role for sTREM-1 in the evolution
of infectious diseases, and indicates that the soluble receptor form
represents a useful marker of infection, particularly for the
diagnosis of nosocomial sepsis [18] and pneumonia [18,21,22].
Two possible sources of sTREM-1 have been postulated:
translation of an alternative TREM-1 mRNA splice variant and
proteolytic cleavage (shedding) of mature, cell surface-anchored
TREM-1 [7]. We have recently described that matrix metallo-
proteinases (MMPs) are responsible for shedding TREM-1
ectodomain from the cell membrane, most likely through
proteolytic cleavage of a single peptide bond within the long
juxtamembrane linker of the membrane-bound receptor [9].
These findings imply that sTREM-1 generation requires a
previous expression of the membrane-anchored receptor.
Here we have tested the hypothesis that the high frequency of
infection observed in CF patients is at least partly the consequence
of deregulated innate immune responses. To this end, we have
explored the expression of (1) receptors involved in LPS
recognition (CD14 and TLR4/MD2), (2) the down-regulator of
the TLR pathway, IRAK-M, and (3) both membrane-bound and
soluble forms of TREM-1. We demonstrate that TREM-1 levels
are clearly down-regulated in monocytes from patients when
compared to healthy volunteers and to patients suffering from
another pulmonary disease, COPD. Further, sTREM-1 was not
detected in the sera of cystic fibrosis patients, and monocytes from
these patients challenged ex vivo with LPS neither up-regulated
TREM-1 nor its soluble form. On the basis of these findings, we
conclude that polymicrobial lung infections in patients who suffer
from cystic fibrosis are due at least partly to a deficiency in their
innate immune responses, and that impaired TREM-1 expression
plays a role in this deficiency.
Materials and Methods
Reagents
All reagents were of the highest quality available and were
obtained from Merck (Darmstadt, Germany), Boehringer (Man-
nheim, Germany), or Sigma-Aldrich (St. Louis, MO). Lipopoly-
saccharide (LPS, from Salmonella abortus) was generously provided
by Dr. Chris Galanos from the Max Planck Institut fu ¨r
Immunobiologie, Freiburg, Germany. The anti–TREM-1 and
anti-TLR4 antibodies were purchased from R&D Systems (MN,
USA); anti-CD14-PE, anti-CD16b and anti-CD1a were obtained
from Serotec (Oxford, UK), anti-p65 from Santa Cruz (CA, USA),
and anti-PU.1 from Cell Signaling (Danvers, MA).
Patients and controls
We studied 20 non-smoker adults diagnosed with CF on the
basis of established criteria (CFTR genotyping, sweat testing, and
clinical phenotype) [23], who did not use inhaled or oral
corticosteroids within the three months previous to the study.
We also studied and ten consecutive clinically stable patients with
moderate-severe COPD (post-bronchodilator FEV1,80% of
predicted and FEV1/forced vital capacity (FVC)#70%) [24].
Exclusion criteria included a history of asthma, other active lung
disease, mental or physical handicap, or other significant diseases,
such as congestive heart failure, ischemic or valvular cardiopathy
or neuromuscular disease. None of the subjects had experienced
an exacerbation or respiratory tract infection within the previous
four weeks, and none of them showed significant bronchodilator
reversibility (either .12% of baseline FEV1 or .200 ml). No
subject has had oral corticosteroid therapy for at least three
months. Moreover, ten sex- and age-matched healthy volunteers
without neither personal history of CF nor other significant illness
were also included as controls.
The following clinical variables were collected on each subject
using chart review: age, sex, body mass index, CFTR genotype,
dyspnea evaluated by the modified Medical Research Council
(MRC) scale [25], arterial blood gases, basal spirometry,
moderate-severe COPD exacerbations in the last year, COPD
severity [26], microorganisms in sputum, and usual therapy. Blood
samples were taken from patients and healthy donors. Peripheral
blood mononuclear cells (PBMCs) were isolated and monocytes
cultured under various conditions. Plasma from patients and
healthy donors was also used for other assays (see below). Written
informed consent was obtained from all subjects (patients and
healthy volunteers). This study was approved by the local Ethics
Committee (La Paz Hospital Ethics Committee, Paseo de La
Castellana 261, Madrid 28046).
Human monocytes isolation and culture
PBMCs were isolated from blood of healthy donors and CF
patients by centrifugation on Ficoll-Hypaque Plus (Amershan
Biosciences, Netherlands) following previously reported protocols
[27,28]. Cells were initially cultured for 2 h to a density of
10
6 cells/ml in DMEN supplemented with antibiotics (100 IU/ml
penicillin and 100 mg/ml streptomycin). After this period, the
supernatant was removed and adherent cells (2610
6 per well) were
cultured in the same medium supplemented with 10% heat-
inactivated fetal bovine serum. Purity of all cultures was verified by
CD14+ staining; on average 89% of the cells presented this surface
marker. Cells were then cultured in the presence or absence of
10 ng/ml LPS for different periods of time (range: from 1 to
16 hours).
FACS analysis of CD14, TLR4/MD2 and TREM-1 expression
Monocytes from healthy volunteers and patients were washed in
PBS and incubated with anti-CD14, anti–TREM-1 or anti-
TLR4/MD2 antibodies followed by an anti-goat FITC-conjugat-
ed secondary polyclonal antibody (Jackson Immunoresearch,
Baltimore, USA). To correct unspecific binding, appropriate
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and TREM-1), cells were incubated with a CD14- allophycocya-
nin (APC)-conjugate (Miltenyi, Bergisch Gladbach, Germany).
Samples were analyzed by flow cytometry using a BD FACSCa-
libur flow cytometer (BD Biosciences, San Diego, CA) equipped
with a 25 mW argon laser. The same protocol was followed in
cases of cultures stimulated with LPS.
ELISA quantitation of sTREM-1
Concentrations of sTREM-1 in supernatants of human
monocyte cultures from patients and controls were determined
using a commercially available ELISA (DuoSet, R&D Systems),
following the manufacturer’s instructions (lower limit of detection:
15 pg/ml).
Immunohistochemistry
Cells were fixed for 15 min with 2% paraformaldehyde in PBS,
pH 7.3. Then, samples were blocked using a blocking serum
(Universal Quick Kit, Vector Laboratories, CA), rinsed, and finally
labeled by incubating overnight at 4 uC with anti–TREM-1
antibody diluted 1:1,000 in PBS. The cells were washed twice in
20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.2% Tween 20
(TTBS) and incubated with a secondary FITC-conjugated
antibody (1:4,000) for one hour. After rinsing with TTBS, cell
nuclei were labeled by incubating with Hoechst 33342 (Molecular
Probes), a cell-permeable fluorescent die that can therefore stain
nuclei of both living and fixed cells. Briefly, Hoechst stock solution
(2 mM in saline) was diluted in PBS (1:8,000) and cells were
incubated with this solution for 5–10 minutes at room tempera-
ture. Samples were then rinsed three times with PBS, excess buffer
was drained, and samples finally mounted in anti-fade mounting
medium. Cells were viewed and photographed on a Leica
DMI6000 B (Leica Microsistemas, S.A.).
RNA and protein isolation
Cells were washed once in PBS and their RNA was isolated
using TRI-Reagent (IMICO, Cincinnati, OH). Purified RNA was
treated with RNase-free DNase I (Amersham Biosciences) and
cDNA was obtained by reverse transcription of 1 mg RNA using a
poly(dT) oligonucleotide primer (Roche, Palo Alto, CA). Protein
fractions were isolated as recommended (Roche), and the final
pellets were dissolved in a solution containing 1% SDS.
mRNA quantification
The expression levels of TNFa, IL-6, IRAK-M, and 18S were
analyzed by real time Q-PCR (LightCycler; Roche Diagnostics,
Indianapolis, IN), using cDNA obtained as described above. Real
time Q-PCR was performed using a Fast-Start DNA master SYBR
Green system (Roche) and specific primers (listed in Table 1). All
results were normalized to the expression of the 18S gene, and the
cDNA copy number of each gene of interest was determined using
a seven-point standard curve. Standard curves were run with each
set of samples, the correlation coefficients r
2 being .0.99. To
confirm the specificity of the reaction products in each experiment,
the melting profile of each sample was analyzed using the
LightCycler. Melting profiles were determined by maintaining the
reactions at 80uC for 10 s and then increasing the temperature to
95uC at a linear rate of 0.1uC/s while measuring the emitted
fluorescence. Analysis of the melting curves demonstrated that
each pair of primers amplified a single product. PCR products
were separated in agarose gels and stained with ethidium bromide
to confirm that in each case a single fragment of the predicted size
had been amplified. For 18S mRNA detection we used the primers
of QuantumRNA Classic 18S provided by Ambion, USA. All
other primers were purchased from IZASA (Barcelona, Spain) and
their specific PCR conditions are listed en Table 2.
Isolation of nuclear proteins
A procedure based on the method reported by Lopez-Collazo et
al [29] was used. Cells were washed twice with ice-cold PBS, and
plates were filled with 0.4 ml Buffer A (20 mM Tris-HCl, pH 7.8,
5 mM MgCl2, 10 mM KCl, 0.5 mM EGTA, 0.5 mM DTT,
1 mM PMSF, and 10 mM leupeptin). The cells were scraped off
the dishes using a rubber policeman and transferred to 1.5-ml
Eppendorf tubes, to which Nonidet P-40 was added to reach a
0.5% final concentration. The tubes were gently vortexed for 15 s
and nuclei were sedimented by centrifugation at 8,0006g for 15 s.
Aliquots of the supernatant were stored at 280uC (cytosolic
extract), and the nuclear pellet was resuspended in 100 ml Buffer A
supplemented with 0.4 M KCl. Nuclear proteins were extracted
by centrifugation at 13,0006g for 15 min, and aliquots of the
supernatant were stored at 280uC. All steps of cell fractionation
were conducted at 4uC.
SDS-PAGE and Western blotting
Cell extracts and nuclear proteins were boiled in Laemmli
buffer, resolved on 15% SDS–polyacrylamide gels in Tris/
glycine/SDS buffer, and transferred to Immun-Blot PVDF
Membranes (Bio-Rad, CA) at 300 mA for 1.5 h at 4uC. After
blocking for 1 h in TTBS containing 5% non-fat milk, membranes
were washed three times in TTBS alone and probed for 20 h with
anti–TREM-1, anti-p65 or anti-PU.1 antibodies diluted in TTBS.
Following extensive washing in TTBS, membranes were incubat-
ed for 45 min with a secondary HRP-conjugated antibody (diluted
1:4,000), and finally washed three times with TTBS. The bound
antibodies were detected using ECL Plus reagents according to the
manufacturer’s instructions (Amersham–Pharmacia Biotech, Hol-
land).
Prostaglandin E2 quantitation
Levels of PGE2 in sera and supernatants of cultures of
monocytes from CF patients and healthy controls were measured
using a commercial available kit (R&D Systems) and following the
manufacturer’s instructions.
Table 1. Sequences of oligonucleotides used for Q-PCR
analysis.
Gene Sense primer (39R59) Antisense primer (39R59)
TNFa GCCTCTTCTCCTTCCTGATCGT CTCGGCAAAGTCGAGATAGTCG
IL-6 CAAAGAATCTAGATGCAATAA GCCCATTAACAACAACAATCTG
IRAK-M TTTGAATGCAGCCAGTCTGA GCATTGCTTATGGAGCCAAT
doi:10.1371/journal.pone.0002667.t001
Table 2. PCR conditions for mRNA quantitation.
Gene Tm (uC) Cycles
TNFa 64 95uC for 10 s, 64uC for 10 s, 72uC for 19 s
IL-6 50 95uC for 10 s, 50uC for 10 s, 72uC for 10 s
IRAK-M 59 95uC for 10 s; 59uC for 10 s 72uC for 19 s
doi:10.1371/journal.pone.0002667.t002
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The number of experiments analyzed is indicated in each figure.
The statistical significance was calculated using the unpaired
Student’s test and differences were considered significant at p
values,0.05.
Results
Patients
Clinical and genetic data of CF patients included in the current
study (n=20) are shown in Table 3. Their mean age was 30610
years (mean6SD); their FEV1 (% predicted) was 61621%, their
FEV1/FVC ratio 696102% and the mean incidence of pulmo-
nary exacerbations in the previous year was 1.8 episodes (range, 0–
5). In agreement with the genetic distribution in the Spanish
population, nine patients (45%) were homozygous for the CFTR
variant DF508 and other nine were compound heterozygotes, with
one copy of DF508 plus another mutation. Pseudomonas aeruginosa
colonization was identified in 14 CF patients (70%).
Mean age of moderate-severe COPD patients was 6967 years,
with a mean post-bronchodilator FEV1 of 53620% predicted and
a FEV1/FVC ratio of 45612% (Table 4). The incidence of COPD
exacerbations (2.2 episodes/year) was similar to that of the CF
patients. All patients were informed of our study. This study was
approved by the local Ethics Committee (La Paz Hospital Ethics
Committee, Paseo de La Castellana 261, Madrid 28046).
Circulating monocytes from cystic fibrosis patients fail to
mount an appropriate inflammatory response in the
presence of Gram-negative endotoxin
Because CF patients are frequently colonized by different
bacteria [30,31], we decided to study innate immune responses in
circulating monocytes isolated from these patients. First, we
cultured these cells in the presence or absence of LPS for 1, 6 or
16 hours, and verified production of pro-inflammatory cytokines.
This analysis revealed low TNFa and IL-6 mRNA expression
levels in monocytes isolated from CF patients (in following termed
CF monocytes), while cells from healthy volunteers were able to
induce significant amounts of these two cytokines after LPS
challenge (Fig. 1, A and B). We note in particular that one-hour
LPS treatment was enough to induce a clear expression of TNFa
mRNA, which remained high for at least six hours. By contrast,
CF monocytes failed to potently up-regulate this cytokine. Similar
results were observed with IL-6 levels, but maximal expression in
healthy volunteers was observed 6 h after LPS challenge, and the
difference between normal and CF monocytes was not so
pronounced.
In addition, we also studied production of soluble TNFa in the
supernatants of these cultures. In line with our findings regarding
mRNA transcription, high levels of TNFa protein were detected
16 hours after LPS stimulation in monocytes isolated from
healthy volunteers. By contrast, cells from CF patients produced
Table 3. Clinical data of cystic fibrosis patients included in the current study. MAC, Mycobacterium avium complex.
Subject
Age
(yr) Gender
BMI
(Kg/m
2) CFTR mutation
FEV1
(%)
FEV1/
FVC(%)
Microorganisms in
sputum
Inhaled
bronchodilator
Human
DNase?
Inhaled
antibiotics
1 23 M 20.2 DF508 / ? 59.5 55.9 P. aeruginosa Formoterol No Colimycin
2 39 M 25.1 DF508 / DF508 87.4 81.4 P. aeruginosa Salbutamol 2.5 mg/d Tobramycin
3 28 F 20.1 DF508 / ? 66.2 82.2 H. influenzae, S. aureus Formoterol No None
4 31 M 17.7 DF508 / DF508 21.6 48.8 C. albicans Salmeterol,
salbutamol
2.5 mg/d None
5 23 F 18.3 DF508 / W1282x 76.3 88.8 H. influenzae, S. aureus,
P. aeruginosa
Formoterol 2.5 mg/d Tobramycin
6 30 F 21.8 DF508 / ? 32.8 65.3 P. aeruginosa Salbutamol,
ipratropium
No Colimycin
7 30 M 25.2 DF508 / DF508 73.8 70.6 P. aeruginosa Salmeterol No Tobramycin
8 28 F 18.5 DF508 / ? 80.1 75.2 H. influenzae, S. aureus, MAC Salbutamol No None
9 28 M 22.3 DF508 / ? 81.0 79.1 B. cepacia None No None
10 21 M 23.2 R553 / 2789+5G-.A 85.2 72.9 S. aureus, P. aeruginosa None No Tobramycin
11 29 M 21.8 DF508 / DF508 33.9 48.4 P. aeruginosa Salmeterol,
salbutamol
No Colimycin
12 68 F 26.3 DF508 / DF508 65.0 70.3 P. aeruginosa Salmeterol No None
13 32 M 22.8 DF508 / DF508 79.4 75.1 P. aeruginosa Salbutamol No None
14 22 F 23.0 DF508 / DF508 35.9 55.4 S. aureus, P. aeruginosa Formoterol,
salbutamol
2.5 mg/d Tobramycin
15 27 F 20.8 R334W / 1069delICA 47.5 66.2 P. aeruginosa Salmeterol,
salbutamol
No Tobramycin
16 26 M 21.1 DF508 / ? 82.4 76.2 H. influenzae, S. aureus,
P. aeruginosa
None No None
17 31 M 22.4 DF508 / DF508 51.2 64.3 P. aeruginosa Salmeterol No Tobramycin
18 24 M 21.7 DF508 / ? 83.2 71.7 H. influenzae, S. aureus None No None
19 23 F 20.3 DF508 / DF508 43.1 65.9 P. aeruginosa Formoterol No Colimycin
20 28 F 23.7 DF508 / ? 39.8 67.0 P. aeruginosa Salbutamol,
salmeterol
No Tobramycin
doi:10.1371/journal.pone.0002667.t003
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conclude that CF monocytes fail to mount a strong innate
immune response upon LPS challenge. We note that all
monocyte cultures were reasonably pure, as illustrated by the
presence of an average of 89% CD14-positive cells in both
healthy controls and CF patients, with negligible levels of CD16b
and CD1a staining (Fig. 1D).
Circulating monocytes from CF patients exhibit normal
levels of TLR4 and MD2 at their cell surface, and do not
overexpress IRAK-M
Once established that CF monocytes fail to respond properly to
ex vivo LPS challenge, and having observed similar levels of CD14
expression in these cells and in control monocytes (Figs 1D and
2A), we decided to analyze the expression of the two other proteins
involved in LPS recognition and signaling, MD2 and TLR4. It is
well known that this Toll-like receptor together with CD14 and the
soluble carrier, MD2, form the receptor complex for LPS in
human monocytes [32]. Thus, abnormalities in TLR4 and/or
MD2 expression could offer a straightforward explanation for the
LPS desensitization phenomenon observed in CF monocytes.
However, and in contrast to our expectations, normal levels of
these two proteins were found at the cell surface, and the flow
cytometric analysis of TLR4/MD2 expression did not show
significant differences between healthy controls and CF patients in
this regard (Fig. 2B).
We have previously described that the pseudokinase, IRAK-M,
is overexpressed in monocytes from patients who suffer from Acute
Coronary Syndrome, and is involved in the endotoxin tolerance
phenomenon observed in these monocytes [33]. Next, and
considering this negative role within the TLR signaling pathway,
we determined IRAK-M expression levels in LPS-stimulated
monocytes [27,34,35]. However, despite a slight tendency to
IRAK-M down-regulation in CF monocytes compared to controls,
no significant differences were observed in the kinetics of
expression of this pseudokinase (Fig. 3).
TREM-1 is expressed at low levels in circulating
monocytes from cystic fibrosis patients
Impaired up-regulation of TNFa and IL-6 (Fig. 1) would suggest
that CF monocytes are not able to mount a strong inflammatory
response after LPS challenge. This defective response to endotoxin is
mostlikely not due to impaired LPS recognition bythe MD2-CD14-
TLR4complex,asthethree proteins arenormally expressed inthese
cells (Fig. 2), nor to IRAK-M overexpression (Fig. 3). Therefore, we
reasoned that a downstream positive feed-back loop could be
affected in CF monocytes. Because of its repeated association with
polymicrobial infections, and in particular with lung infections
[17,36,37,38], we hypothesized that decreased expression of another
receptor involved in inflammatory responses, TREM-1, could lead
to the observed LPS unresponsiveness in patients monocytes, with
concomitant impairment of inflammatory responses. Although the
actual role of TREM-1 in the innate immune response is not well
understood, current evidence strongly supports a key role for this
receptor as an amplifier of inflammatory responses, in particular
during polymicrobial sepsis (see Introduction and refs [6,39]).
To verify this hypothesis, we compared TREM-1 levels in
monocytes isolated from CF patients versus healthy volunteers.
Indeed, a significant down-regulation of membrane-anchored
TREM-1 was observed in CF monocytes (Fig. 4, A and B). These
findings indicate that basal levels of TREM-1 are about two-fold
lower in circulating monocytes from CF patients than in healthy
individuals, and suggest a possible explanation for the observed
inability of these cells to mount an inflammatory response.
We have recently reported that expression levels of TREM-1 at
the monocyte surface are controlled by endogenous metallopro-
teinases, which cleave membrane-anchored TREM-1 to generate
the soluble form, sTREM-1 [9]. High levels of soluble TREM-1
have been identified by others in patients suffering from diverse
infectious diseases [8,16] and in particular in their fluids
[14,15,17,18,19,20]. Our previous findings suggest that LPS first
induces an appreciable up-regulation of TREM-1 at the cell
surface of human monocytes, but this membrane-anchored form is
Table 4. Clinical data of Chronic Obstructive Pulmonary Disease patients included in the current study. NAC, N-Acetyl-Cystein, …
Subject Gender
Age
(yr)
BMI
(Kg/m
2)
FVC
(%)
FEV1
(%)
FEV1 /
FVC
PaO2
(mmHg)
PaCO2
(mmHg) MRC
Exacerbations
last year /
Grade Treatment
1 M 82 23.6 109 73 0.49 55.8 41.6 4 3 / IV LTOT, salmeterol, fluticasone (2000 mcg), ipratropium,
NAC, salbutamol
2 M 69 29.1 77 33 0.33 67.5 42.8 2 4 / III Salmeterol, fluticasone (1000 mcg), tiotropium,
salbutamol, NAC
3 M 68 25.2 59 21 0.27 68.8 48.4 3 2 (3) / IV Salmeterol, fluticasone (1000 mcg), tiotropium,
teophiline, NAC, salbutamol
4 M 68 23.5 100 44 0.35 78.0 37.3 2 0 / III Tiotropium, salbutamol
5 M 65 22.9 77 35 0.35 60.5 55.5 2 1 / III Formoterol, budesonide (800 mcg), tiotropium,
salbutamol
6 M 73 28.0 69 43 0.48 56.1 46.1 2 2 / III Salmeterol, fluticasone (2000 mcg), tiotropium,
salbutamol
7 F 66 30.5 133 75 0.47 73.0 35.2 1 3 / II Salmeterol, fluticasone (1000 mcg), tiotropium,
salbutamol
8 M 59 28.7 84 67 0.63 78.6 34.6 2 2 / II Tiotropium, salbutamol
9 M 79 29.3 90 68 0.56 69.9 32.0 2 0 / II Salmeterol, ipratropium
10 M 63 34.8 92 69 0.59 58.3 38.6 4 5 / II Salmeterol, fluticasone (1000 mcg), ipratropium,
teophilline, NAC, salbutamol
doi:10.1371/journal.pone.0002667.t004
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production and/or activation, which generates sTREM-1 via
proteolytic cleavage of the full-length receptor [9]. Thus, these
clear differences in TREM-1 levels at the monocyte surface could
be explained by the presence of a pathogen infection in CF
patients. In particular, LPS generated by Gram-negative patho-
gens could induce metalloproteinase expression and activation,
and concomitant shedding of TREM-1 extracellular domain. To
test this possibility we compared the levels of sTREM-1 in sera
from CF patients vs. healthy controls. However, no significant
differences were found between both groups, and levels of
sTREM-1 were low (,0.2 ng/ml) in both CF patients and
healthy volunteers (Fig. 4C). These ELISA data were further
confirmed via Western blot analysis (Fig. 4D).
Circulating monocytes from CF but not COPD patients
fail to overexpress TREM-1 at the cell surface upon LPS
stimulation
Previous studies have demonstrated a fast up-regulation of
membrane-anchored TREM-1 expression after LPS challenge
[7,8]. Considering our previous findings, we next analyzed levels
of TREM-1 in CF monocytes stimulated with LPS. As we have
shown before [9], a time course analysis of TREM-1 expression
revealed that levels of this receptor increase in a time-dependent
manner in monocytes isolated from healthy controls, reaching a
maximum (three-fold increase over basal levels) about six hours
after LPS challenge (Fig. 5A and B, gray bars). TREM-1
expression increased to similar levels in COPD monocytes 1 h
after stimulation, but appeared to reach a maximum earlier than
in control monocytes (Fig. 5A and B, hatched bars). In striking
contrast, receptor expression was not up-regulated in CF
monocytes upon ex vivo endotoxin stimulation (Fig. 5A and B,
solid bars). In addition, and to exclude that the observed effect
might be due to a reduction in the number of TREM-1 positive
cells, we performed another experiment with monocytes isolated
from five of each of the three groups studied (randomly selected
from the previously discussed sets). Cultures of circulating
monocytes were stimulated, or not, with LPS for 1 hour. Next,
cells were double-stained with TREM-1-FITC and CD14-APC,
and analyzed by flow cytometry. As figure 5C shows, about 90%
of cells were CD14+ in all conditions analyzed. Control cells
stimulated with LPS exhibit an average of 40% CD14+/TREM-1
positive cells, and a similar result was obtained for COPD
monocytes. In contrast, CF cells exhibit low levels of CD14+/
TREM-1+ cells (less than 5%), and they did not increase
significantly their basal levels of TREM-1 after LPS stimulation.
Figure 1. Inflammatory responses are impaired in monocytes from CF patients. Monocytes from healthy volunteers (control, gray bars, n=10)
andfromCFpatients(CF,solidbars,n=20)wereculturedinthepresenceof10 ng/mlLPSforindicatedtimes.Cellswereharvested,totalRNAisolatedand
cDNA synthesized. TNFa (A) and IL-6 (B) mRNA levels were analyzed by real time Q-PCR. The ratios [TNFa]/[18S] and [IL-6]/[18S] are depicted. **, p,0.01
with respect to healthy controls (C) Concentrations of TNFa were determined in supernatants of cultures of human monocytes from healthy volunteers
(control, gray bars, n=10) and CF patients (CF, solid bars, n=20), stimulated or not with 10 ng/ml LPS. *, p,0.05 with respect to healthy controls. (D)
Monocytes isolated from healthy volunteers (control, gray bars, n=10) and CF patients (CF, solid bars, n=20) were stained with anti-CD14-PE, anti-CD16b
or anti-CD1a antibodies and then analyzed by flow cytometry; the fraction of cells stained with each antibody is given.
doi:10.1371/journal.pone.0002667.g001
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COPD monocytes (data not shown).
We also verified that sTREM-1 is not detected in supernatants
of untreated cultures of human monocytes isolated from healthy
volunteers, which implies levels below 15 pg/ml. However,
concentration of this soluble form was notably enhanced in the
supernatants of both control and COPD cultures after 16 hours of
LPS stimulation (Fig. 5D). In our model, reduced cell surface
expression of TREM-1 was always accompanied by a concomitant
increase in sTREM-1 levels in culture supernatants. By contrast,
cultures of CF monocytes did not contain detectable levels of
sTREM-1 after LPS stimulation (Fig. 5D, solid bars).
We further confirmed these results by immunofluorescence and
Western blot analysis. As shown in Figure 6A, significant TREM-1
expression is observed in cultures of human monocytes treated
with LPS for 6 h but not in those cells isolated from CF patients.
In addition, these experiments clearly demonstrate membrane
localization of mature TREM-1. On the other hand, the absence
of sTREM-1 in the supernatant of CF cultures was confirmed by
Western blotting (Fig. 6B).
Figure 2. Elements of the LPS receptor complex are expressed at similar levels in control and CF monocytes. Monocytes isolated from
healthy volunteers (control, gray bars, n=10) and CF patients (CF, solid bars, n=20) were stained with anti-CD14 and anti-TLR4/MD2 and then
analyzed by flow cytometry; the fraction of cells stained is given (A and B respectively). Typical histograms are shown in the insets (I, isotype; Control,
healthy volunteers; CF, Cystic Fibrosis).
doi:10.1371/journal.pone.0002667.g002
Figure 3. IRAK-M is normally induced in CF monocytes after LPS stimulation. Cultures of human monocytes from healthy volunteers
(control, gray bars, n=10) and CF patients (CF, solid bars, n=20) were treated with 10 ng/ml LPS for indicated times. Next, cells were harvested, total
RNA isolated and cDNA synthesized as described in Material and Methods. The ratio of IRAK-M to 18S is shown.
doi:10.1371/journal.pone.0002667.g003
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regulation in CF monocytes
It has been recently demonstrated that prostaglandin E2
(PGE2) plays an important role in the control of TREM-1
expression [13]. In particular, Murakami and coworkers suggest
that LPS-induced TREM-1 expression on macrophages is
mediated by endogenous PGE2. To examine possible mecha-
nisms underlying TREM-1 down-regulation in CF patients, we
determined levels of PEG2 in monocytes from CF and healthy
volunteers. However, and contrary to expectations, there were no
significant differences in PGE2 concentrations between CF and
control monocytes (Fig. 7). This finding indicates that other
factors in addition to PEG2 modulate TREM-1 expression in
human monocytes.
High levels of nuclear PU.1 in circulating monocytes from
cystic fibrosis patients
It has been recently reported that activation of the transcription
factor p65 is necessary for expression of TREM-1, whereas
another transcription factor, PU.1, inhibits TREM-1 up-regula-
tion [40]. PU.1 is highly expressed in cells of the immune system
and regulates several genes in, e.g., macrophages and B cells [41].
Apparently, in response to LPS challenge both factors bind to the
TREM-1 promoter in macrophages. To analyze possible mecha-
nisms underlying TREM-1 down-regulation in CF patients, we
determined levels of p65 and PU.1 in nuclei isolated from CF
monocytes and healthy volunteers. As Figure 8 shows, PU.1 but
not p65 is differentially activated in untreated monocytes from CF
patients versus controls. These findings suggest that PU.1
Figure 4. Expression levels of TREM-1 and sTREM-1 are low in CF monocytes. (A) Monocytes isolated from healthy volunteers (controls,
gray bars, n=10) and CF patients (CF, solid bars, n=20) were stained with anti–TREM-1-FITC and then analyzed by flow cytometry; the fraction of
cells stained is given as % of total cells (left scale) and as mean fluorescence intensity (MFI, right scale). *, p,0.05 with respect to healthy controls. (B)
A typical histogram obtained from flow cytometric analysis of TREM-1 expression is shown (I, isotype; CF, CF patients; Control, healthy volunteers). (C)
The concentration of sTREM-1 in the supernatants of the same cultures was analyzed with a commercial ELISA. The mean concentration of sTREM-1 is
represented. (D) Supernatants from monocyte cultures (one from a healthy volunteer (control) and two from randomly selected CF patients) were
centrifuged at 4006g to remove detached cells and possible cellular debris. A Western blot analysis of these supernatants was performed using an
anti–TREM-1 commercial antibody that recognizes the extra-cellular domain of TREM-1. Human monocytes challenged with LPS for six hours were
used as positive control (+). Notice detection of a band of approximately 27 kDa in this condition (marked with an arrow). Loading controls are also
shown (membrane stained with Ponceau red, lower panel). The results of a triplicated experiment are shown.
doi:10.1371/journal.pone.0002667.g004
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TREM-1 down-regulation in cystic fibrosis patients.
Discussion
Although previous investigations have revealed a hyperinflam-
matory state in CF patients [42,43,44], the observed high
frequency of pathogen colonization in these patients points to a
significant deficiency of their innate immune systems. Several
studies conducted so far have focused on local and resident cells
(e.g., lung epithelial cells or recruited neutrophils), and have
demonstrated a defective IL-8 secretion by CF-airway epithelial
cells in these patients [45]. On the other hand, a recently
published article presents an interesting mechanism by which
neutrophils fail to be activated in CF patients’ lungs [46]. The
unopposed elastolytic activity in the airways of individuals with CF
leads to CXCR1 cleavage on neutrophils, thus disabling their
bacterial-killing capacity.
In contrast, the inflammatory responses of circulating cells in
CF patients have not been properly described so far. Previous
works indicate that levels of TNFa in CF patients could be either
higher [42] or lower than in healthy volunteers [43]. These
differences appear to be due to the presence of P. aeruginosa
infection and/or antibiotic treatment, but the small number of
enrolled patients (14 and 10, respectively) does not allow for a
statistically meaningful comparison. Here we show that monocytes
isolated from twenty CF patients, fourteen of which were
colonized by P. aeruginosa (see Table 3), are unable to mount a
proper inflammatory response when they are challenged ex vivo
with the major immunogenic component of Gram-negative
bacteria, LPS. Besides, this feature is irrespective of the presence
or absence of P. aeruginosa infection. The low levels of two critical
pro-inflammatory cytokines, TNF-a and IL-6, produced by these
cells indicate that they could not properly respond to a bacterial
insult (Figure 1). Our findings are in agreement with the
significantly lower IL-8 production in DF508 CF cell line
compared to a normal airway epithelial cells after LPS challenge
[47], but are at odds with the higher levels of TNFa expression in
CF monocytes stimulated with LPS recently reported by others
[44]. This discrepancy might result from the use of a 10-fold
Figure 5. CF but not COPD monocytes fail to induce TREM-1 expression after LPS stimulation. (A) Cultures of human monocytes from
healthy volunteers (control, gray bars, n=10) CF patients (CF, solid bars, n=20) and COPD patients (COPD, hatched bars, n=10) were treated with
10 ng/ml LPS for indicated times. Next, cells were harvested and stained with anti-TREM-1-FITC and analyzed by flow cytometry. The fraction of
positive cells is given as % of total cells (A) and MFIs (B). The percentage of CD14 and TREM-1 positive cells was analyzed in monocytes from five of
each of the studied groups (i.e., CF patients, COPD patients and healthy individuals; all samples were randomly selected), treated or not ex vivo with
LPS for 1 hour. The flow cytometry analysis of these cells simultaneously stained with CD14-APC and TREM-1-FITC is shown (C). Supernatants from
the same experiment (shown in panels A and B) were centrifuged at 4006g to remove detached cells and possible cellular debris. The concentration
of sTREM-1 in the supernatants was analyzed with a commercial ELISA. The mean concentration of sTREM-1 in ng/ml is given (D). *, p,0.05 and **,
p,0.01 with respect to similarly treated monocytes from healthy individuals.
doi:10.1371/journal.pone.0002667.g005
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only nine patients were included in the latter study. Additional
studies of immune responses by CF monocytes enrolling a larger
number of patients will be needed to gain further insight into the
mechanisms that ultimately result in chronic lung colonization in
these patients.
Our current results suggest that the observed refractory state in
CF patients was not secondary to impaired LPS recognition by
circulating CF monocytes. Indeed, we observed normal levels of
TLR4, MD2 and CD14 in cells from CF patients and healthy
individuals; similar observations were made for other elements of
the intracellular TLR signaling pathway. These data are in line
with those reported by Muir and coworkers, who showed that the
expression of TLRs is not directly affected by CFTR dysfunction
in different types of airway epithelial cells [47].
Note that in our experiments we have used a purified
lipopolysaccharide from Salmonella abortus generously provided by
Dr. Chris Galanos (Max Planck, Freiburg, Germany). Recently, a
thorough study that compared endotoxins from different sources
indicated that LPS from S. abortus is more potent than the one
generated by the bacteria most commonly found in CF patients, P.
aeruginosa [48]. Despite this, ex vivo stimulation of CF monocytes
with S. abortus LPS did not generate the pro-inflammatory response
observed in cells from healthy controls. It is therefore safe to
assume that challenging CF monocytes with P. aeruginosa LPS
would lead to similar or even less pronounced responses.
Several recent reports demonstrate an important role for
TREM-1 in inflammation during an infectious disease; the
receptor appears to act as an amplifier of the immune response
Figure 6. TREM-1 is not induced in CF monocytes upon LPS
challenge. (A) Cultures of human monocytes from healthy volunteers
and CF patients were treated with 10 ng/ml LPS for 6 hours, stained with
an anti–TREM-1 antibody (green), and nuclei were localized via standard
staining with Hoechst 33342 (blue). A typical result of three independent
experiments is shown (I, anti-TREM-1; II, merged anti-TREM-1 and Hoechst
33342). (B) Cell supernatants from monocyte cultures (one from a healthy
volunteer (control) and two from randomly selected CF patients) were
stimulated with LPS or not (0) for 6 and 18 h, and then centrifuged at
4006g to remove detached cells and possible cellular debris. A Western
blot analysis of these supernatants was performed using an anti–TREM-1
commercial antibody that recognizes the extracellular domain of the
receptor. Notice detection of a band of approximately 27 kDa in this
condition (arrow). Loading controls are also shown (membrane stained
with Ponceau red, lower panel). The results of a typical experiment from
three experiments performed are shown.
doi:10.1371/journal.pone.0002667.g006
Figure 7. Levels of PGE2 are similar in CF monocytes and
controls. Cultures of human monocytes from healthy volunteers
(control, gray bars, n=10) and CF patients (CF, solid bars, n=20) were
treated with 10 ng/ml LPS for indicated hours. Next, levels of PGE2 were
analyzed using a PGE2 EIA kit.
doi:10.1371/journal.pone.0002667.g007
Figure 8. Levels of PU.1 but not of p65 are up-regulated in CF
monocytes. Nuclear protein fractions were isolated from circulating
monocytes obtained from healthy volunteers (control, gray bars, n=5)
and CF patients (CF, solid bars, n=10). Western blot analysis was
performed using anti-p65 and anti-PU.1 antibodies. Normalization was
carried out with an anti-a-actin antibody. The average of densitometer
analysis of each Western blot is shown (n=5). *, p,0.05 with respect to
healthy controls.
doi:10.1371/journal.pone.0002667.g008
LPS Tolerance in CF-Patients
PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e2667in the presence of pathogens [6,11,12,17,39]. In line with these
findings, we observed that circulating monocytes from patients
who suffer from CF showed significantly decreased basal levels of
TREM-1. In addition, the receptor was not up-regulated upon
LPS stimulation ex vivo. These observations suggest that down-
regulation of surface exposed TREM-1 might at least partly
underlie the non-responsiveness state in CF patients.
Previous work from our laboratory indicated that soluble
TREM-1 is generated after LPS challenge or pathogen infection
via limited proteolysis of membrane-anchored receptor by LPS-
activated matrix metalloproteinases [9]. However, the low levels of
TREM-1 expression on the cell surface of CF monocytes do not
seem to be explained by proteolytic processing of the full-length
receptor, as there are no significant differences in sTREM-1 levels
found in CF patients and healthy volunteers. Thus, the clear
disparity in TREM-1 levels on the monocyte surface between CF
and controls cannot be explained by an exacerbated proteolytic
attack secondary to pathogen infection in CF patients. In this
regard, we notice that the kinetics of TREM-1 expression upon
LPS stimulation was not significantly different in healthy
volunteers and in the extra control group of COPD patients
included in our study (see Table 4). Similar results have been
recently reported by Radsak and co-workers [49]. Further,
analysis of proinflammatory cytokines revealed that COPD
monocytes are not locked in an endotoxin tolerance state (data
not shown).
Both PGE2 and p65 have been described as positive regulators
of TREM-1 expression [13,40]. However, our results also seem to
exclude a reduction in PGE2 levels and deficient activation of p65
as part of the molecular mechanism that leads to the observed
tolerance state. On the other hand, the transcription factor PU.1 is
known to block TREM-1 expression in murine macrophages [40].
In line with this finding, we have detected high levels of PU.1 in
nuclei isolated from CF monocytes.
Currently, we can only speculate about the mechanisms that
link defective CFTR functioning to TREM-1 down-regulation.
One appealing hypothesis is that changes in the ion concentrations
in CF patients induce PU.1 activation and subsequent TREM-1
down-regulation in their monocytes [40]. Interestingly, Xu and co-
workers have reported that IL-1b and the related S100 calcium-
binding proteins, calgranulin A and B (S100A8 and A9,
respectively), are up-regulated in mice with CFTR deficiency
[50]. In fact, elevated concentrations of these proteins, which have
been alternatively termed CF antigen (CFAg), have long been
detected in serum from CF patients [51,52]. On the other hand,
other authors have demonstrated that both IL-1b [53,54] and
S100A8 / A9 are induced upon PU.1 activation [55,56]. Also
along these lines, a recent study suggests a clear down-regulation
of the transcriptional repressor, Foxp1, in cftrD508 mice [57];
independent studies have established that this occurs in the
presence of high levels of PU.1 [58]. Altogether, a likely pathway
of monocyte inactivation in CF patients begins to emerge. Several
lines of evidence indicate that transcription factor PU.1 is activated
in CF models, perhaps in response to an elevated intracellular
calcium concentration [59]. The transcription factor then
accumulates at high levels in nuclei of human CF monocytes,
ultimately resulting in TREM-1 repression. The final result is a
diminished expression of membrane-anchored TREM-1, which
aborts the positive feed-back loop needed for mounting a strong
response against invading pathogens.
In conclusion, our data suggest that circulating monocytes from
CF patients are ‘‘locked’’ in an endotoxin tolerance state, which
results at least in part from a notable down-regulation of TREM-1
expression. These findings open new avenues for the character-
ization and treatment of inflammatory responses in CF patients.
Our results suggest that not only resident immune cells but also
circulating monocytes are affected in CF patients, and are unable
to respond properly to LPS challenge. We suggest that this
information should be considered while developing new anti-
infection therapies in CF patients.
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